Copy link
Export CSV
Cite this view
HANK Price Transparency. (n.d.).
50242-0150-01 - OCRELIZUMAB 300 MG/10 ML SOL (OTHER 4758008) by State .
PPMan price-transparency data, derived from CMS-required hospital MRFs.
Retrieved June 29, 2026 , from http://ppman.hank.ai/transparency/procedure/4758008/by-state?code_type=OTHER
“50242-0150-01 - OCRELIZUMAB 300 MG/10 ML SOL (OTHER 4758008) by State.” HANK Price Transparency ,
http://ppman.hank.ai/transparency/procedure/4758008/by-state?code_type=OTHER. Accessed
June 29, 2026 .
“50242-0150-01 - OCRELIZUMAB 300 MG/10 ML SOL (OTHER 4758008) by State,” HANK Price Transparency ,
accessed June 29, 2026 ,
http://ppman.hank.ai/transparency/procedure/4758008/by-state?code_type=OTHER.
Source: PPMan price-transparency data, derived from CMS-required hospital
machine-readable files (45 CFR 180). See
methodology .
Print / Save PDF
OTHER · across United States
4758008 — 50242-0150-01 - Ocrelizumab 300 Mg/10 Ml Sol
State-by-state median negotiated rates. Lower bars are cheaper states; the
range bar shows the IQR (25th to 75th percentile within each state).
$39,334
National median
$34,393 – $43,742
IQR (p25 – p75)
1
hospitals filing
1
states
Median negotiated rate, by state
Ranked by typical (median) negotiated price. Hover for state-level IQR.
Median negotiated rate by state for 4758008 (OTHER), with interquartile range
State Median p25 p75
CO $39,334 $34,393 $43,742